Mayo Clinic and Mayo Medical Laboratories have signed a collaboration agreement with bioTheranostics to offer CancerTYPE ID® molecular cancer classification test, as part of its surgical pathology consultations, to aid in the management of patients with metastatic cancer.
Recent Stories for Research
A clinical trial led by researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital indicates that a new drug can often prevent a common, sometimes severe viral disease in patients receiving a transplant of donated blood-making stem cells. In a paper in the Sept. 26 issue of the New England Journal of Medicine, the researchers report that patients who took the drug CMX001 shortly after transplant were far less likely to develop cytomegalovirus (CMV) infection than were patients who took a placebo.
Researchers have discovered why multiple myeloma, a difficult to cure cancer of the bone marrow, frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. Working in collaboration with colleagues at Princess Margaret Cancer Centre in Toronto, researchers from Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) in Phoenix were part of the team that conducted the study published in the Sept. 9 issue of “Cancer Cell.”
Other Posts for Research
- UC Irvine and Mayo Clinic researchers establish most precise relationship between the calendar and vitamin D levels
- Expanding geographic range increases importance of testing for tick-borne diseases
- From ASCO: Are CT Scans Needed for Lymphoma?
- Mayo Clinic forms joint venture with Cancer Genetics
- Larazotide Acetate & Celiac Disease [VIDEO]